Oliceridine injection is an investigational next generation IV analgesic for the management of moderate to severe acute pain in the hospital and similar settings and has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Oliceridine injection was specifically designed to improve conventional opioid pharmacology to deliver the pain-reducing potential of an opioid but with fewer opioid-related adverse effects. Oliceridine is an investigational product and has not been approved by the FDA or any other regulatory agency. If approved, the Company expects oliceridine to be a Schedule II controlled substance.